Elevance Health, Inc. Q1 2025 Filing Summary
Business Context and Reporting Period
This summary covers the Form 10-Q for Elevance Health, Inc. for the quarterly period ended March 31, 2025. Elevance is one of the largest U.S. health insurers, serving approximately 45.8 million medical members as of the reporting date. The company operates through four reportable segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It is an independent licensee of the Blue Cross and Blue Shield Association (BCBSA).
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 | Change |
|---|---|---|---|
| Total Operating Revenue | $48,765 million | $42,273 million | +15.4% |
| Net Income | $2,184 million | $2,249 million | -2.9% |
| Diluted EPS | $9.61 | $9.59 | +0.2% |
| Operating Cash Flow | $1,017 million | $1,978 million | -48.6% |
| Cash & Equivalents | $7,500 million | $8,288 million | -9.5% |
| Total Debt | $29,728 million | $30,842 million | -3.6% |
| Debt-to-Capital Ratio | 41.3% | 43.0% | -1.7 pp |
| Benefit Expense Ratio | 86.4% | 85.6% | +80 bp |
| Operating Expense Ratio | 10.9% | 11.6% | -70 bp |
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased by $6.5 billion (15.4%), driven by premium rate increases in the Health Benefits segment, growth in Medicare Advantage and Individual ACA membership, and recent acquisitions. CarelonRx product revenue also grew significantly.
- Profitability Pressure: Despite revenue growth, Net Income declined by $65 million (2.9%). This was primarily due to a decrease in operating gain within the Health Benefits segment (driven by Medicaid rates being inadequate to cover medical cost trends), increased operating losses in Corporate & Other, and higher net losses on financial instruments ($464 million vs. $161 million).
- Membership Trends: Total medical membership decreased by 0.5% to 45.8 million. This decline was driven by attrition in Medicaid (due to eligibility redeterminations) and Commercial Fee-Based businesses, partially offset by growth in Medicare Advantage (+11.8%) and Individual ACA (+14.2%).
- Cash Flow: Operating cash flow decreased significantly ($961 million) primarily due to timing-related changes in working capital, specifically a $3.2 billion increase in receivables.
- Capital Allocation: The company repurchased $880 million of common stock and paid $386 million in dividends. It also repaid $1.25 billion in long-term borrowings.
Guidance, Outlook, and Risks
- Star Ratings Impact: The company expects a reduction in 2026 operating revenue of approximately $183 million due to a decline in Medicare Advantage Star Ratings (38% of members in 4.0+ star plans vs. 53% in the prior year). Management plans to mitigate this through contract diversification and expense efficiencies.
- Regulatory Environment: Continued Medicaid eligibility redeterminations are expected to impact membership through 2025. The expiration of enhanced Premium Tax Credits at the end of 2025 poses a risk to Individual Public Exchange enrollment if not extended by Congress.
- Acquisitions: Recent acquisitions of Centers (long-term care) and CareBridge (home/community-based services) are expected to drive growth in the Health Benefits and Carelon Services segments.
- Litigation: The company is involved in the BCBSA Antitrust Litigation. A Provider Settlement Agreement was preliminarily approved in December 2024, with an estimated payment obligation of $666 million recognized in September 2024. A final fairness hearing is scheduled for July 2025.
- Investment Losses: Net losses on financial instruments increased significantly due to losses on other invested assets and equity securities, including a $396 million liability recognized for amended put options related to the Liberty Dental joint venture.
Key Facts for Investor Verification
- Verify the sustainability of the Medicaid benefit expense ratio (86.4%) given the stated inadequacy of rates to cover medical cost trends.
- Monitor the impact of the Medicare Advantage Star Rating decline on 2026 revenue and the effectiveness of management's mitigation strategies.
- Assess the timing of working capital changes that caused the sharp drop in operating cash flow, specifically the $3.2 billion increase in receivables.
- Track the status of the BCBSA Provider Settlement and potential follow-on litigation from opt-out entities.
- Review the net losses on financial instruments ($464 million) to understand the volatility in the investment portfolio and the impact of the Liberty Dental put option amendment.